Irish drug firm's shares jump on testing result

Amryt develops so-called orphan drugs, or treatments for extremely rare diseases or conditions with a lack of mainstream available treatments. File image

Shares in Irish drug development company Amryt Pharma surged by as much as 51% on the back of it reporting positive late-stage trial results for its potential treatment for rare skin disease Epidermolysis Bullosa (EB).

Amryt – which recently scrapped its Dublin share listing in favour of the Nasdaq – develops so-called orphan drugs, or treatments for extremely rare diseases or conditions with a lack of mainstream available treatments.